Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.36 |
| ▸ | HRH2 | P25021 | 4/20 | 0.36 |
| ▸ | HRH1 | P35367 | 4/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8068236 | 0.84 | HRH2 (0.39) | SCN9AHRH2HRH1CTSCPTPN1 | |
| SCHEMBL8069233 | 0.79 | HRH2 (0.35) | HRH2HRH1CTSCGPR119F2 | |
| SCHEMBL8058055 | 0.78 | ELANE (0.36) | HRH2HRH1ACEGPR119F2 | |
| SCHEMBL2891309 | 0.76 | GPR119 (0.45) | HRH2HRH1GPR119XIAPF2 | |
| SCHEMBL2891305 | 0.76 | GPR119 (0.45) | HRH2HRH1GPR119XIAPF2 | |
| SCHEMBL2900663 | 0.76 | GPR119 (0.45) | HRH2HRH1GPR119 | |
| SCHEMBL2900659 | 0.76 | GPR119 (0.45) | HRH2HRH1GPR119 | |
| SCHEMBL8066212 | 0.75 | PTPN1 (0.37) | HRH2HRH1PTPN1GPR119 | |
| SCHEMBL8057985 | 0.74 | HRH2 (0.35) | HRH2HRH1PTPN1GPR119 | |
| SCHEMBL8080722 | 0.73 | HRH2 (0.36) | HRH2HRH1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |